To the Editor Rigotti et al1 provide a critical addition to the literature for which there is a dearth of information: the treatment of nicotine dependence in individuals who use e-cigarettes. Of note, the posttreatment decline in abstinence rates in this phase 2 trial is worthy of further comment. The decline was twice as prevalent in the cytisinicline group compared to the placebo group (鈭�26.4% vs 鈭� 12.6%), narrowing the gap in abstinence to 23.4% vs 13.2%, respectively.